Clinical Trials Directory

Trials / Completed

CompletedNCT06742242

The Use of Non-ICG-Enhanced Lymphatic Vessels for LVA

The Use of Non-Indocyanine Green-Enhanced Lymphatic Vessels for Supermicrosurgical Lymphaticovenous Anastomosis: a Propensity-Score-Matched Outcome Analysis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
106 (actual)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
20 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The aim of the present study was to investigate the impact of non-ICG(+) LVs on the outcomes after LVA compared to ICG(+) LVs with propensity-score-match analysis.

Detailed description

It is a common belief among lymphatic supermicrosurgeons that LVA should only be performed with indocyanine green-enhanced (ICG(+)) LVs since such LVs are considered functional and are suitable for achieving better outcomes. However, in moderate to advance lymphedema patients, the use of non-ICG(+) LVs are inevitable despite efforts to identified ICG(+) LVs with ICG lymphography10, magnetic resonance (MR) lymphangiography11, or ultrasound12. In a previous study, it was suggested that a non-ICG(+) but flow-positive LV should also be considered functional because the functionality of an LV should be determined by its capability to transport lymph instead of ICG(+) lymph. Therefore, non- ICG(+) but flow-positive LVs should also be used for LVA to maximize the outcome13. This hypothesis was further supported by a recent article emphasizing the concept of a lymphatic-based lymphosome14, where it has been demonstrated that a functional LV will not become ICG(+) when ICG is not injected in the region being drained by this particular LV. It offers an explanation as to why a supposedly functional LV is not enhanced by ICG.

Conditions

Interventions

TypeNameDescription
PROCEDURElymphaticovenous anastomosissupermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation

Timeline

Start date
2015-09-01
Primary completion
2023-03-01
Completion
2023-03-01
First posted
2024-12-19
Last updated
2024-12-19

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT06742242. Inclusion in this directory is not an endorsement.